Narcolepsy was first identified almost 130 years ago, but it was only 15 years ago that it was identified as a neurodegenerative disease linked to a loss of orexin neurons in the brain. It is unclear what causes the orexin neurons to die, but our strategy has been to place the gene for orexin into surrogate neurons in the validated mouse models of narcolepsy, and test whether it can block narcolepsy symptoms, such as cataplexy. In both the orexin knockout and the orexin-ataxin-3 mouse models of narcolepsy we have found that cataplexy can be blocked if the surrogate neurons are part of the circuit responsible for cataplexy. We have also determined that the orexin gene can be inserted into surrogate neurons in the amygdala to block emotion-induced cataplexy. Through the use of optogenetics we anticipate that it will be possible to preemptively block cataplexy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511086 | PMC |
http://dx.doi.org/10.1016/j.conb.2017.03.017 | DOI Listing |
Int J Mol Sci
December 2024
A.V. Zhirmunsky National Scientific Center of Marine Biology, Far Eastern Branch, Russian Academy of Sciences, 690041 Vladivostok, Russia.
Sleep is the most important physiological function of all animals studied to date. Sleep disorders include narcolepsy, which is characterized by excessive daytime sleepiness, disruption of night sleep, and muscle weakness-cataplexy. Narcolepsy is known to be caused by the degeneration of orexin-synthesizing neurons (hypocretin (HCRT) neurons or orexin neurons) in the hypothalamus.
View Article and Find Full Text PDFJMIR Public Health Surveill
January 2025
Centre of Sleep Medicine and Epileptology Barmelweid, Klinik Barmelweid AG, Aargau, Switzerland.
Background: Stimulants are potent treatments for central hypersomnolence disorders or attention-deficit/hyperactivity disorders/attention deficit disorders but concerns have been raised about their potential negative consequences and their increasing prescription rates.
Objective: We aimed to describe stimulant prescription trends in Switzerland from 2014 to 2021. Second, we aimed to analyze the characteristics of individuals who received stimulant prescriptions in 2021 and investigate the link between stimulant prescriptions and hospitalization rates in 2021, using hospitalization as a potential indicator of adverse health outcomes.
medRxiv
December 2024
Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, School of Brain Science and Brain Medicine, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310058, China.
We present the Large PSG Model (LPSGM), a unified and flexible framework for sleep staging and disease diagnosis using polysomnography (PSG) data. LPSGM is designed to address the challenges of cross-center generalization in sleep staging and to enable fine-tuning for downstream disease diagnosis tasks. LPSGM introduces a unified training framework for heterogeneous datasets and allows flexible channel input adjustments during inference.
View Article and Find Full Text PDFJ Med Internet Res
December 2024
Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Background: Patient experience data from social media offer patient-centered perspectives on disease, treatments, and health service delivery. Current guidelines typically rely on systematic reviews, while qualitative health studies are often seen as anecdotal and nongeneralizable. This study explores combining personal health experiences from multiple sources to create generalizable evidence.
View Article and Find Full Text PDFInt J Mol Sci
November 2024
Department of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang 471003, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!